Lomond Therapeutics, a subsidiary of Eilean Therapeutics LLC, today announced an abstract related to the company's Lomonitinib, a highly potent and selective pan-FLT3/IRAK4 inhibitor that targets ...

Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology ...

Curis Inc. ( (CRIS) ) has released its Q3 earnings. Here is a breakdown of the information Curis Inc. presented to its investors. Curis Inc. is ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning, ladies and gentlemen, and welcome to the Curis ...

Curis, Inc. ("Curis") , a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and ...

For an explanation of our use of non-GAAP financial measures refer to the "Use of Non-GAAP Financial Measures" section later ...

Sanofi has high hopes for two asthma candidates – TSLP-targeting lunsekimig and oral BTK inhibitor rilzabrutinib – along with an anti-TL1A drug for inflammatory bowel disease, an IRAK4 ...

It reckons that its antibodies will be able to target the underlying cause of autoimmune diseases, unlike current therapies such as steroids or TNF and interleukin inhibitors that while effective ...

The study provides a valuable showcase of a workflow to perform large-scale characterization of drug mechanisms of action using proteomics in which on-target and off-targets of 166 compounds using ...